| 000 | 00000nam 2200000zi 4500 |
| 001 | 9.917987 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20230120113052 |
|---|
| 006 | m o d f |
|---|
| 007 | cr mn||||||||| |
|---|
| 008 | 221205e20221209onc ob f000 0 eng d |
|---|
| 020 | |a9780660465814 |q(report) |
|---|
| 020 | |a9780660465821 |q(summary) |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aHP5-141/1-1-2022E-PDF |
|---|
| 086 | 1 |aHP5-141/2-1-2022E-PDF |
|---|
| 245 | 00|aUpdated recommendations on the use of COVID-19 vaccine booster doses in children 5 to 11 years of age and concurrent vaccine administration. |
|---|
| 264 | 1|aOttawa, ON : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |cDecember 9, 2022. |
|---|
| 264 | 4|c©2022 |
|---|
| 300 | |a1 online resource (24 pages) + |esummary (5 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aIssued also in French under title: Recommandations mises à jour sur l'utilisation des doses de rappel du vaccin contre la COVID-19 chez les enfants de 5 à 11 ans et sur l'administration concomitante de vaccins. |
|---|
| 500 | |aOn cover: An advisory committee statement (ACS), National Advisory Committee on Immunization (NACI). |
|---|
| 500 | |a"Pub.: 220625." |
|---|
| 500 | |a"Pub.: 220627." |
|---|
| 504 | |aIncludes bibliographical references (pages 18-24). |
|---|
| 650 | 0|aCOVID-19 vaccines|zCanada. |
|---|
| 650 | 0|aCOVID-19 (Disease)|xVaccination|zCanada. |
|---|
| 650 | 0|aVaccination of children|zCanada. |
|---|
| 650 | 0|aCOVID-19 vaccines|xGovernment policy|zCanada. |
|---|
| 650 | 0|aCOVID-19 (Disease)|xVaccination|xGovernment policy|zCanada. |
|---|
| 650 | 0|aVaccination of children|xGovernment policy|zCanada. |
|---|
| 710 | 2 |aPublic Health Agency of Canada, |eissuing body. |
|---|
| 710 | 1 |aCanada. |bNational Advisory Committee on Immunization, |eissuing body. |
|---|
| 775 | 08|tRecommandations mises à jour sur l'utilisation des doses de rappel du vaccin contre la COVID-19 chez les enfants de 5 à 11 ans et sur l'administration concomitante de vaccins.|w(CaOODSP)9.917988 |
|---|
| 795 | |tRecommendations on the use of a first booster dose of Pfizer-BioNTech Comirnaty COVID-19 vaccine in children 5 to 11 years of age.|w(CaOODSP)9.914493 |
|---|
| 856 | 40|qPDF|s1.57 MB|uhttps://publications.gc.ca/collections/collection_2023/aspc-phac/HP5-141-1-1-2022-eng.pdf|z(report) |
|---|
| 856 | 40|qPDF|s817 KB|uhttps://publications.gc.ca/collections/collection_2023/aspc-phac/HP5-141-2-1-2022-eng.pdf|z(summary) |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/updated-recommendations-use-covid-19-vaccine-booster-doses-children-5-11-years-concurrent-administration.html|z(report) |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/updated-recommendations-use-covid-19-vaccine-booster-doses-children-5-11-years-concurrent-administration/summary-december-9-2022.html|z(summary) |
|---|
| 986 | |a220625 |
|---|
| 986 | |a220627 |
|---|